Horizon Pharma (HZNP) Tops Q2 EPS by 11c, Raises FY Guidance

August 7, 2019 7:03 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Horizon Pharma (NASDAQ: HZNP) reported Q2 EPS of $0.49, $0.11 better than the analyst estimate of $0.38. Revenue for the quarter came in at $320.6 million versus the consensus estimate of $297.69 million.


Horizon Pharma sees FY2019 revenue of $1.28-1.3 million, versus the consensus of $1.26 million.

  • The Company now expects full-year 2019 net sales to range between $1.28 billion to $1.30 billion, an increase from the previous guidance range of $1.26 billion to $1.28 billion. Full-year 2019 adjusted EBITDA is now expected to range between $460 million to $475 million, an increase from the previous guidance range of $450 million to $465 million.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities